Gb Sciences, Inc. Receives Positive Preclinical Results in an Interim Report from Its Study Using Preclinical Zebrafish Models of Stress At the National Research Council of Canada
October 24, 2022 at 12:07 pm
Share
Gb Sciences, Inc. has received positive preclinical results in an interim report from its study using preclinical zebrafish models of stress at the National Research Council of Canada (NRC). GbS' proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study. The NRC is testing GbS' proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending PhAROS(TM) (Phytomedical Analytics for Research Optimization at Scale) platform to identify these combinations of plant compounds for novel drug candidates. These are the company's first non-cannabis formulations
to advance in preclinical studies. For these novel psychotropic drug candidates, the Gb Sciences research team used the PhAROS(TM) platform to identify new ingredients to improve upon an initial formulation for anxiety based on traditional medicine. The original plant mixture was derived from the kava plant, but some elements of kava are thought to cause liver toxicity. PhAROS(TM) identified ingredients from the Piper plant family as a substitute for the functionality of the ingredients in question without the potentially adverse safety profiles of those original ingredients. The Piper plant family includes pepper plants that are used worldwide in traditional medicines. The PhAROS(TM) platform is a revolutionary, AI-driven science gateway and virtual research environment for drug discovery. With its data analytics and machine learning capabilities, PhAROS(TM) allows Gb Sciences to greatly reduce the time and money required to bring novel, plant-inspired formulations to market. PhAROS(TM) represents a breakthrough combination of data sciences and traditional plant-based medicines.
GB Sciences, Inc. is a biopharmaceutical research and development company. The Company develops disease-targeted formulations of cannabis and other plant-inspired therapeutic mixtures for the prescription drug market through its wholly owned subsidiary, GbS Global Biopharma, Inc. (GBSGB). The Company's primary focus is on preparing its lead program for the treatment of the motor symptoms of Parkinson's disease (PD) in a human clinical trial. Through GBSGB, the Company is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB has a portfolio of intellectual property containing both plant-inspired formulations and its artificial intelligence (AI)-enabled drug discovery platform, as well as research contracts and various supplier arrangements. GBSGBs intellectual property covers a range of over 65 medical conditions, from which five drug development programs are in the preclinical stage of drug development.
Gb Sciences, Inc. Receives Positive Preclinical Results in an Interim Report from Its Study Using Preclinical Zebrafish Models of Stress At the National Research Council of Canada
GB SCIENCES, INC. 
